ID

13251

Description

Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission; ODM derived from: https://clinicaltrials.gov/show/NCT00834002

Link

https://clinicaltrials.gov/show/NCT00834002

Keywords

Versions (1)
  1. 1/26/16 1/26/16 -
Copyright Holder

CC BY-NC 3.0

Uploaded on

January 26, 2016

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Acute Myeloid Leukemia (AML) NCT00834002

English

Eligibility Acute Myeloid Leukemia (AML) NCT00834002

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. tumor type: acute myeloid leukemia (aml) according to the who criteria (ea at least 20% blasts in the marrow). all fab subtypes except m3. patients with myelodysplastic syndrome, category of refractory anemia with excess blasts (raeb): raeb i (who: medullary blast count ≤ 10% and a peripheral blast count ≤ 5%) and raeb ii (who: medullary blast count > 10% and/or > 5% peripheral blasts) can be included in the study in absence of other non-experimental treatment modalities.
Description

AML, MDS

Data type

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2]
C3463824
2. extent of disease: remission (partial or complete) or smouldering course. complete remission (cr) is defined as no blasts in the peripheral blood and no more than 5% blasts in the bone marrow. this definition is related to the hematological remission if it is not specified. partial remission (pr) is defined as a decrease of at least 50% in the percentage of blasts to 5 to 25% in the bone marrow aspirate. smouldering course is defined as a relatively low marrow blast count and slowly progressive disease.
Description

remission

Data type

boolean

Alias
UMLS CUI [1]
C0544452
3. overexpression of wt1 rna (>50 copies of wt1 per 1000 copies abl in bone marrow or >2 copy/1000 copies abl in peripheral blood) as assessed by quantitative rt-pcr at the time of presentation.
Description

wt1 expression

Data type

boolean

Alias
UMLS CUI [1]
C0694898
4. prior treatments : patients must have received at least one prior antileukemic chemotherapeutic regimen and must be more than 1 month past the last treatment and/or 6 months past allogeneic/autologous stem cell transplantation.
Description

prior treatment

Data type

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1504389
5. age: ≥ 18 years
Description

age: ≥ 18 years

Data type

boolean

Alias
UMLS CUI [1]
C0001779
6. high risk of relapse because of (and/or) age > 60 years (if <60 y, no sibling allotransplant donor available) poor risk cytogenetic or molecular markers at presentation second complete remission after relapse hyperleukocytosis at presentation
Description

high risk of relapse

Data type

boolean

Alias
UMLS CUI [1]
C0277556
7. performance status: who ps grade 0-1 (appendix b)
Description

WHO performance status

Data type

boolean

Alias
UMLS CUI [1]
C1298650
8. objectively assessable parameters of life expectancy: more than 3 months
Description

life expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
9. prior and concomitant associated diseases allowed with the exception of underlying autoimmune disease and positive serology for hiv/hbv/hcv
Description

prior and concomitant associated diseases allowed with the exception of underlying autoimmune disease and positive serology for hiv/hbv/hcv

Data type

boolean

Alias
UMLS CUI [1]
C0009488
10. no concomitant use of immunosuppressive drugs
Description

immunosuppressive agents

Data type

boolean

Alias
UMLS CUI [1]
C0021081
11. adequate renal and liver function, i.e. creatinin and bilirubin = 1.2 times the upper limit of normal
Description

renal and liver function

Data type

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C1278039
12. absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Description

absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Data type

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
13. women of child-bearing potential should use adequate contraception prior to study entry and for the duration of study participation
Description

contraception

Data type

boolean

Alias
UMLS CUI [1]
C0700589
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. subjects with concurrent additional malignancy (with exception of non-melanoma skin cancers and carcinoma in situ of the cervix)
Description

malignancy

Data type

boolean

Alias
UMLS CUI [1]
C0006826
2. subjects who are pregnant
Description

pregnancy

Data type

boolean

Alias
UMLS CUI [1]
C0032961
3. subjects who have sensitivity to drugs that provide local anesthesia
Description

sensitivity to drugs that provide local anesthesia

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0002921
4. age < 18 years
Description

age < 18 years

Data type

boolean

Alias
UMLS CUI [1]
C0001779
Back to the top of the page

Similar models

Eligibility Acute Myeloid Leukemia (AML) NCT00834002

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
AML, MDS
Item
1. tumor type: acute myeloid leukemia (aml) according to the who criteria (ea at least 20% blasts in the marrow). all fab subtypes except m3. patients with myelodysplastic syndrome, category of refractory anemia with excess blasts (raeb): raeb i (who: medullary blast count ≤ 10% and a peripheral blast count ≤ 5%) and raeb ii (who: medullary blast count > 10% and/or > 5% peripheral blasts) can be included in the study in absence of other non-experimental treatment modalities.
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2])
remission
Item
2. extent of disease: remission (partial or complete) or smouldering course. complete remission (cr) is defined as no blasts in the peripheral blood and no more than 5% blasts in the bone marrow. this definition is related to the hematological remission if it is not specified. partial remission (pr) is defined as a decrease of at least 50% in the percentage of blasts to 5 to 25% in the bone marrow aspirate. smouldering course is defined as a relatively low marrow blast count and slowly progressive disease.
boolean
C0544452 (UMLS CUI [1])
wt1 expression
Item
3. overexpression of wt1 rna (>50 copies of wt1 per 1000 copies abl in bone marrow or >2 copy/1000 copies abl in peripheral blood) as assessed by quantitative rt-pcr at the time of presentation.
boolean
C0694898 (UMLS CUI [1])
prior treatment
Item
4. prior treatments : patients must have received at least one prior antileukemic chemotherapeutic regimen and must be more than 1 month past the last treatment and/or 6 months past allogeneic/autologous stem cell transplantation.
boolean
C0392920 (UMLS CUI [1])
C1504389 (UMLS CUI [2])
age: ≥ 18 years
Item
5. age: ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
high risk of relapse
Item
6. high risk of relapse because of (and/or) age > 60 years (if <60 y, no sibling allotransplant donor available) poor risk cytogenetic or molecular markers at presentation second complete remission after relapse hyperleukocytosis at presentation
boolean
C0277556 (UMLS CUI [1])
WHO performance status
Item
7. performance status: who ps grade 0-1 (appendix b)
boolean
C1298650 (UMLS CUI [1])
life expectancy
Item
8. objectively assessable parameters of life expectancy: more than 3 months
boolean
C0023671 (UMLS CUI [1])
prior and concomitant associated diseases allowed with the exception of underlying autoimmune disease and positive serology for hiv/hbv/hcv
Item
9. prior and concomitant associated diseases allowed with the exception of underlying autoimmune disease and positive serology for hiv/hbv/hcv
boolean
C0009488 (UMLS CUI [1])
immunosuppressive agents
Item
10. no concomitant use of immunosuppressive drugs
boolean
C0021081 (UMLS CUI [1])
renal and liver function
Item
11. adequate renal and liver function, i.e. creatinin and bilirubin = 1.2 times the upper limit of normal
boolean
C0201976 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Item
12. absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
contraception
Item
13. women of child-bearing potential should use adequate contraception prior to study entry and for the duration of study participation
boolean
C0700589 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
malignancy
Item
1. subjects with concurrent additional malignancy (with exception of non-melanoma skin cancers and carcinoma in situ of the cervix)
boolean
C0006826 (UMLS CUI [1])
pregnancy
Item
2. subjects who are pregnant
boolean
C0032961 (UMLS CUI [1])
sensitivity to drugs that provide local anesthesia
Item
3. subjects who have sensitivity to drugs that provide local anesthesia
boolean
C0020517 (UMLS CUI [1,1])
C0002921 (UMLS CUI [1,2])
age < 18 years
Item
4. age < 18 years
boolean
C0001779 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial